Biotech · Private company
Avirmax Biopharma Inc
Track this companyFree. Adds Avirmax Biopharma Inc to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- ABI-110 High DosePhase 2 · Neovascular (Wet) AMDClinicalTrials.gov · fetched Nov 12, 2026
- ABI-110 Low DosePhase 2 · Neovascular (Wet) AMDClinicalTrials.gov · fetched Nov 12, 2026
- ABI-110 Medium DosePhase 2 · Neovascular (Wet) AMDClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 7, 2024ClinicalTrials.gov NCT06550011 · fetched Nov 12, 2026